Navigate today’s most pressing health industry challenges with a leading global expert by your side.
ACO utilization & cost evaluation
Healthcare cost modeling
Insurance risk assessment
Medicare plan selection solution
Healthcare risk adjustment
Pharmaceutical claims analytics
Meet growing needs for innovative insurance solutions while increasing operational health and improving compliance.
Property & casualty advisory services
Modern flood insurance program
Investment, advisory & trading services
Financial modeling & industrialization
Geographic rating insights
Premium comparison platform
Retirement & Benefits
Deliver on the promises of the past and create smart solutions for the future.
Pension administration & communication
Retirement benefits administration platform
Compensations & benefits
Benefit plan evaluation
Health & welfare benefits administration platform
Manage complex risks using data-driven insights, advanced approaches, and deep industry experience.
Auto policy underwriting
Software performance enhancement
Mortgage platform for investments & reinsurance
Solvency II reporting & compliance
This is a place where your ideas and insights make an impact. Where an independent, entrepreneurial spirit is an advantage. And where diversity of thought and experience makes us who we are.
Data-driven insight. Deep expertise. Transformative innovation. Since 1947, Milliman has delivered intelligent solutions to improve health and financial security.
Analyze the emerging market to support underwriting, pricing, and product development.
Milliman DNA Gene and Cell Therapy Forecasting
Compiling baseline assumptions and developing a rigorous approach to inform and test scenarios is challenging for a number of reasons:
Milliman DNA is an interactive, web-based application with two primary components: a research repository and a dynamic online interface.
Create informed offerings and policies based on populated data and research.
Help customers learn about gene and cell therapies and their potential treatment-eligible members.
Improve underwriting processes and guidelines with the most comprehensive information available.
Acquire the latest information on approvals and changes in the gene and cell therapy market.
Focus on deep dives related to sources of uncertainty and key assumptions.
Identify the conditions with the highest potential impact to prioritize for cost or reimbursement mitigation tactics.
Specify the plan year and age distribution to establish baseline assumptions for a commercial, Medicare or Medicaid group.
Export simulations of the scenarios for additional modeling of benefit design features or risk mitigation techniques.
Receive updates on FDA approval status, price announcements, and new therapies appearing on the FDA review horizon.
See how Milliman DNA gives you the information and flexibility you need to stay on top of this fast-moving market.
Familiarize yourself with the indicated conditions and associated patient population for all single-administration gene and cell therapies in the upcoming 18-month window.
Access multiple output views to explore annual expected cases or costs.
Override baseline assumptions for prevalence, coverage, or demand to create scenarios that can be saved and retrieved.
This research paper examines the prevalence of rare diseases in a U.S. commercial population using claims data.
This paper introduces why self-insured employers with stop-loss coverage may still be exposed to some of the costs of gene and cell therapies, explores considerations and a potential imbalance of financial risk for the self-…
Evaluating multiyear payment arrangements? Assess retention rates for patients with rare diseases.
Insurers, policymakers, and government agencies in the United States may find it useful to have an accurate expectation for the length of enrollment by subscribers with a dependent who suffers from a pediatric rare disease…
When it comes to gene and cell therapies, there are a number of risks and benefits that payers should consider.
Ask the tough questions. We’re ready for them.